ALX ONCOLOGY HOLDINGS INC Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
ALX ONCOLOGY HOLDINGS INC (ALXO) had Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount of $0 as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount · last filed 2022-05-09
- 2022-03-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |